Drug Trial Radar · NCT05438459
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
176
Planned (sponsor's estimate)
Start
Jun 8, 2022
Primary completion
Mar 31, 2032
Study completion Mar 31, 2032
Sponsor
- Lead sponsor
- Kyushu UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GAIA BioMedicine Inc.; Japan Agency for Medical Research and Development
- First posted
- Jun 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I Part : Confirm the safety of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination for advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended number of doses for Phase II part. Phase II Part(Gastric Cancer):Comparative Study Research the efficacy and safety of as a monotherapy or GAIA-102 and pembrolizumab for advanced gastrointestinal cancer of microsatellite stable with malignant ascites at the recommended dose of GAIA-102 decided in the Phase I part. Phase II Part (Pancreatic Cancer): Comparative Study Including a Run-in Cohort Research the efficacy and safety of a combination regimen of GAIA-102 and pembrolizumab added to existing chemotherapy (standard of care) for microsatellite stable advanced pancreatic cancer with malignant ascites at the recommended dosing frequency of GAIA-102 decided in the Phase I part.
Conditions
- Gastric Cancer
- Pancreatic Cancer
Interventions
GAIA-102Biological
GAIA-102: 1 vial (2 x 10\^8 cells) as dose at a fixed dose, on 1 to 3 times by weekly for 3 consecutive weeks.
GAIA-102Biological
GAIA-102: 1 vial (2 x 10\^8 cells) as dose at a fixed dose, on 3 times by weekly for 3 consecutive weeks.
PembrolizumabDrug
Pembrolizumab 200 mg administered on Day 1.
PembrolizumabDrug
Pembrolizumab 200 mg administered on Day 8.
Trifluridine/tipiracil hydrochloride (FTD/TPI)Drug
Trifluridine/tipiracil hydrochloride (FTD/TPI) will be administered orally twice daily for 5 consecutive days, followed by a 2-day rest period. This cycle will be repeated twice, followed by a 14-day rest period. One course consists of this schedule, and the treatment will be repeated in cycles.
Irinotecan hydrochloride hydrateDrug
Intravenous infusion of 70 mg/m² (based on body surface area) over 90 minutes at 2-week intervals.
Calcium levofolinate hydrateDrug
Intravenous infusion of 200 mg/m² (based on body surface area) over 2 hours.
FluorouracilDrug
Immediately after completion of the calcium levofolinate hydrate intravenous infusion, fluorouracil 400 mg/m² (based on body surface area) will be administered by intravenous injection, followed by a continuous intravenous infusion of fluorouracil 2,400 mg/m² (based on body surface area) over 46 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants of Dose Limiting Toxicity (DLT) with GAIA-102 (Phase I)Time frame: Cycle 1 (Cycle period is 28 days)
- Frequency and severity of adverse events(Phase I)Time frame: 2 year
- Overall survival in patients with gastric cancer (Phase II)Time frame: up to 4 years
- Overall survival in patients with pancreatic cancer (PhaseⅡ)Time frame: up to 5 years(up to 5.5 years for the Run-in Cohort)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyushu University Hospital
Fukuoka, Fukuoka, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.